Is Compounded Semaglutide or Tirzepatide Still Legal in 2026?

For about three years, "compounded semaglutide" and "compounded tirzepatide" were legal in a specific, narrow, and temporary way: both drugs were on the FDA's official drug shortage list, and federal law allows compounding pharmacies to prepare a copy of an approved drug when it's officially in shortage. That legal basis ended in 2025. This article lays out exactly what changed, when, and what's actually still legal today — because a huge amount of marketing copy still uses shortage-era language that no longer describes the current rule.

The Legal Basis That Existed, and Why It Was Always Temporary

Compounding pharmacies operate under two sections of the Federal Food, Drug, and Cosmetic Act: 503A covers state-licensed pharmacies and physicians compounding for an individual patient with a prescription; 503B covers larger "outsourcing facilities" that can compound in bulk without a patient-specific prescription, under closer FDA oversight. Neither section normally permits compounding a copy of an approved, patent-protected, non-shortage drug — that would undercut the approval and patent system entirely. The exception both sections share is drug shortage: when the FDA's official shortage list includes a drug, compounders may prepare a version of it, because patients need access the branded manufacturer temporarily can't supply. That's the exact legal basis that made mass compounded semaglutide and tirzepatide possible — not an approval of the drugs themselves, but a shortage-driven exception applied to already-approved medications.

The Shortage Ended — Here Are the Actual Dates

The FDA declared the tirzepatide shortage resolved in December 2024, and the semaglutide shortage resolved on February 21, 2025, citing increased manufacturing capacity from the branded manufacturers¹. Resolving the shortage doesn't instantly stop all compounding — the FDA and state boards built in enforcement-discretion windows to let pharmacies wind down existing patient regimens. For tirzepatide, 503A pharmacies had until February 19, 2025 and 503B outsourcing facilities until March 19, 2025 to stop shortage-based compounding. For semaglutide, 503A pharmacies had until April 22, 2025 and 503B facilities until May 22, 2025¹. As of this writing, both of those windows have long closed. Neither drug currently appears on the FDA's drug shortage list.

What's Still Legal Today Is Narrower Than "Compounded GLP-1s"

The shortage exception is gone, but compounding hasn't disappeared entirely — it's shrunk down to its normal, non-shortage legal basis: patient-specific clinical need. Section 503A still permits a licensed pharmacy or physician to compound a version of an approved drug for an individual patient when there's a documented medical reason the FDA-approved product won't work for them — for example, a genuine allergy to an inactive ingredient in the brand-name pen, or a need for a different strength or dosage form the manufacturer doesn't produce. That's a real, legitimate, and continuing pathway. What it is not is a blanket justification to compound semaglutide or tirzepatide for cost reasons or general availability, the way the shortage exception allowed. Several state pharmacy boards have issued guidance specifically clarifying that "shortage" is no longer a valid stated reason for compounding tirzepatide, now that it's off the federal list¹. Neither drug currently appears on FDA's 503B bulk drug substances list either, which further narrows the large-batch compounding pathway.

This matters directly for anyone evaluating a provider today. A telehealth or clinic site still marketing "compounded semaglutide" or "compounded tirzepatide" in 2026 should be able to articulate the specific, patient-level clinical basis for it — not point to a shortage that officially ended over a year ago. For how to read a provider's pricing and disclosures around this, see our best semaglutide online and best tirzepatide online boards, and for the broader legal-status landscape of peptides generally, see are peptides legal?.

Why This Became a Legal Battleground, Not Just a Policy Note

The end of the shortage exception didn't quietly wind down — it triggered real legal conflict. Compounding pharmacy trade groups sued over the shortage-resolution decisions, arguing the FDA's process for determining the shortage was over didn't adequately account for regional or patient-level access gaps, and that litigation has continued to shape how aggressively the rule gets enforced in practice². That's worth knowing because it means the compounding landscape isn't fully settled even now — enforcement intensity and legal challenges are part of an active, ongoing story, not a rule that was cleanly closed in early 2025 and stayed that way.

Bottom Line

Compounded semaglutide and tirzepatide had a real, if temporary, legal basis: an official FDA shortage declaration that both drugs carried for roughly three years. That shortage is over — tirzepatide's ended in December 2024, semaglutide's in February 2025 — and the enforcement-discretion windows that let pharmacies wind down existing patients closed by mid-2025 for both. What remains legal is narrower and older: patient-specific compounding for a documented individual clinical need, the same standard that applies to any approved drug outside a shortage. A provider still marketing broad "compounded GLP-1" access on shortage-era logic in 2026 is describing a legal basis that no longer applies — and that gap between marketing language and current regulatory status is exactly the kind of thing worth checking before choosing a provider.